This article is more than 5 years old. Information may no longer be current.

LensGen gains funding for presbyopia technology

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Series A funding of $11 million has been released to LensGen Inc. for further development of novel IOL technology intended to address presbyopia, according to a company press release.

A key clinical performance milestone triggered the release of funding as part of a $21 million funding series led by Hoya Group’s corporate investment arm, the release said.

In addition, LensGen, which is developing the “first modular, fluid-optic, curvature changing IOL,” received two broad and comprehensive patents from the U.S. Patent Office protecting its technology, the release said.

“We are thrilled to share the steady progress the LensGen team is making toward our ultimate goal of bringing the Juvene platform to market, Ramgopal Rao, the company’s founder and CEO, said in the release.

The Juvene IOL is designed “to permanently restore clear and continuous vision at all distances for patients with cataracts and presbyopia by mimicking the eye’s natural accommodation process to change shape and adjust focus,” the release said.